Genmab A/S (GMAB) PT Raised to $34 at H.C. Wainwright After DARZALEX Combo Results
Tweet Send to a Friend
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Genmab A/S (NASDAQ: GMAB) to $34.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
